Table 1.
Characteristics of study group.
| Subject ID | Duration of HIV infection (years) | CD4 count (cells/μl)a | Viral load (copies/mL)a | Time on HAART (years) | HAART regimen | Assays performed in blood | Assays performed in LN |
|---|---|---|---|---|---|---|---|
| #10 | 9.1 | 543 | <20 | 8.8 | EFV, 3TC | INT DNA, VOA, FC | NA |
| #12 | 8.4 | 453 | <20 | 2.9 | 3TC/r, ABC | INT DNA, VOA, FC | NA |
| #14 | 10.1 | 1,691 | <20 | 3.5 | EFV, TDF, FTC | INT DNA, VOA, FC | INT DNA, VOA |
| #16 | 25.9 | 487 | <20 | 2 | ETR; DRV/r; RAL | INT DNA, VOA, FC | NA |
| #18 | 2.6 | 376 | <20 | 2.5 | FTC, TDF, EFV | INT DNA, VOA, FC | NA |
| #20 | 25.3 | 480 | <20 | 14.1 | ETR, DRV/r, RAL | INT DNA, VOA, FC | NA |
| #26 | 9.6 | 666 | <20 | 2 | 3TC, ABC, DTG | INT DNA, VOA, FC | INT DNA, VOA |
| #35 | 2.1 | 1,219 | <20 | 1.8 | FTC, TDF, EVG | INT DNA, SEQ, VOA, FC | INT DNA, SEQ, VOA |
| #43 | 2.8 | 605 | <20 | 2.8 | 3TC, ABC, DTG | VOA, FC | NA |
| #45 | 8 | 442 | <20 | 7.9 | FTC, TDF, ETR | INT DNA, VOA, FC | NA |
| #75 | 4.7 | 417 | <20 | 3.2 | FTC, TDF, EFV | INT DNA, VOA | VOA |
| #94 | 7 | 440 | <20 | 6.9 | FTC, TDF, EVG | INT DNA, SEQ, VOA | VOA, SEQ |
| #107 | 1.9 | 598 | <20 | 1.8 | FTC, TDF, EFV | INT DNA, VOA | VOA |
| #077 | 6.6 | 560 | <20 | 6 | 3TC, ABC, DTG | SEQ | SEQ |
| #24 | 10.7 | 629 | <20 | 3.9 | FTC, TDF, EFV | NA | INT DNA, VOA |
| #11 | 16.2 | 811 | <20 | 11.7 | FTC, TDF, ATV/r | NA | INT DNA, VOA |
| #04 | 2.9 | 424 | <20 | 1.8 | EFV, TDF, FTC | NA | INT DNA, VOA |
| #25 | 28.5 | 439 | <20 | 4.6 | FTC, TDF, RAL | NA | INT DNA, VOA |
| #42 | 11.1 | 949 | <20 | 6.6 | FTC, TDF, ATV/r | NA | INT DNA, VOA |
| #106 | 0.1 | 501 | 160,000 | 0 | NA | NA | MC |
| #140 | 0.08 | 427 | 360,000 | 0 | NA | NA | MC |
| #119 | 1.3 | 498 | 13,000 | 0 | NA | NA | MC |
| #124 | 0.06 | 468 | 510,000 | 0 | NA | NA | MC |
| #113 | 31.98 | 594 | 640 | 0 | NA | NA | MC |
| #117 | 5.42 | 504 | 54,000 | 0 | NA | NA | MC |
| #125 | 0.16 | 511 | 17,000 | 0 | NA | NA | MC |
| #118 | 0.06 | 538 | 14,000 | 0 | NA | NA | MC |
| #SA150 | 10 | 578 | 6,900 | 0 | NA | NA | MC |
aCD4 cell count and viral load assessments are at the time of enrollment in the study.
ETR, Etravirine; FTC, Emtricitabine; TDF, Tenofovir disoproxil fumarate; ATV/r, Atazanavir boosted with ritonavir; 3TC, Lamivudine; ABC, Abacavir; DRV/r, Darunavir boosted with ritonavir; EFV, Efavirenz; RAL, Raltegravir; DTG, Dolutegravir; EVG, Elvitegravir; LN, lymph node; INT DNA, integrated DNA; VOA, viral outgrowth assay; FC, flow cytometry; SEQ, sequencing; MC, Mass cytometry; NA, not applicable.